Zealand Pharma EBITDA Margin 2017-2024 | ZLDPF

Zealand Pharma ebitda margin for the quarter ending September 30, 2024 was -1472.73%.

  • Zealand Pharma average ebitda margin for 2023 was -438.53%, a 30.32% increase from 2022.
  • Zealand Pharma average ebitda margin for 2022 was -629.35%, a 90.29% decline from 2021.
  • Zealand Pharma average ebitda margin for 2021 was -330.74%, a 26.48% increase from 2020.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Zealand Pharma EBITDA Margin 2017-2024 | ZLDPF

  • Zealand Pharma average ebitda margin for 2023 was -438.53%, a 30.32% increase from 2022.
  • Zealand Pharma average ebitda margin for 2022 was -629.35%, a 90.29% decline from 2021.
  • Zealand Pharma average ebitda margin for 2021 was -330.74%, a 26.48% increase from 2020.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$146.3B
Gilead Sciences (GILD)$114.5B
Bristol Myers Squibb (BMY)$114.2B
Vertex Pharmaceuticals (VRTX)$108.7B
CSL (CSLLY)$83.4B
Regeneron Pharmaceuticals (REGN)$74.9B
GSK (GSK)$69.3B
Argenex SE (ARGX)$38.7B
Alnylam Pharmaceuticals (ALNY)$31.8B
BioNTech SE (BNTX)$26.8B
Illumina (ILMN)$21.7B
BeiGene (ONC)$20.5B
Biogen (BIIB)$20.5B
Incyte (INCY)$13.9B
Genmab (GMAB)$13.8B
Genmab (GNMSF)$13.7B
Intra-Cellular Therapies (ITCI)$13.4B
Moderna (MRNA)$13.1B
Insmed (INSM)$13B
Bio-Techne Corp (TECH)$12B
BioMarin Pharmaceutical (BMRN)$11.7B
Sarepta Therapeutics (SRPT)$11.3B
Vaxcyte (PCVX)$10.6B
QIAGEN (QGEN)$10.5B
Exelixis (EXEL)$10.3B
Swedish Orphan Biovitrum (BIOVF)$10.1B
Exact Sciences (EXAS)$9.6B
Bio-Rad Laboratories (BIO.B)$9.5B
Repligen (RGEN)$9B
Roivant Sciences (ROIV)$8.1B